Dayle S. Hogg
Directeur des opérations chez Gammadelta Therapeutics Ltd.
Profil
Dayle S.
Hogg is currently a Director at Kesios Therapeutics Ltd.
and the Chief Operating Officer at Gammadelta Therapeutics Ltd.
Previously, Dayle held positions as Principal at Sense Proteomic Ltd., Commercial Manager at Lectus Therapeutics Ltd., and Healthcare Ventures Manager at Touchstone Innovations Investment Management Ltd.
Dayle holds a doctorate degree from the University of Oxford and an undergraduate degree from the University of Leeds.
Postes actifs de Dayle S. Hogg
| Sociétés | Poste | Début |
|---|---|---|
Kesios Therapeutics Ltd.
 Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - |
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Directeur des opérations | 01/01/2017 |
Anciens postes connus de Dayle S. Hogg
| Sociétés | Poste | Fin |
|---|---|---|
Lectus Therapeutics Ltd.
 Lectus Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lectus Therapeutics Ltd. Developed ion channel modulators and therapeutics. The company was founded in December 2002 and was headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 01/04/2011 |
Touchstone Innovations Investment Management Ltd.
 Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Private Equity Investor | - |
Sense Proteomic Ltd.
 Sense Proteomic Ltd. Miscellaneous Commercial ServicesCommercial Services Sense Proteomic Ltd. was a functional proteomics company that develops and use protein-related molecular technologies to enhance the productivity of the drug discovery process and the efficacy of the therapies developed from it. It was headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Formation de Dayle S. Hogg
| University of Leeds | Undergraduate Degree |
| University of Oxford | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Lectus Therapeutics Ltd.
Lectus Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lectus Therapeutics Ltd. Developed ion channel modulators and therapeutics. The company was founded in December 2002 and was headquartered in Cambridge, the United Kingdom. | Health Technology |
Sense Proteomic Ltd.
Sense Proteomic Ltd. Miscellaneous Commercial ServicesCommercial Services Sense Proteomic Ltd. was a functional proteomics company that develops and use protein-related molecular technologies to enhance the productivity of the drug discovery process and the efficacy of the therapies developed from it. It was headquartered in Cambridge, UK. | Commercial Services |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Finance |
Kesios Therapeutics Ltd.
Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
